Skip to main content
Utility menu
Donate
Join
Member Login
Search
Learn About Us
Learn About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Contact
Careers
Support The Mission
Support The Mission
Become a Member
Explore Different Ways to Give
Create a Legacy
Join IASLC's Partners for Thoracic Cancer Care
Recognizing Our Donors
Celebrate IASLC's 50th Anniversary
Celebrate IASLC's 50th Anniversary
History
WCLC 2024 Highlights
Access Online Learning
Conferences & Education
Conferences & Education
Conferences
Webinars
Online Learning: Lung Cancer 360
Lung Cancer Considered Podcast
WCLC 2024
Science & Research
Science & Research
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Scientific Projects
Scientific Projects
IASLC Staging Project: Lung Cancer, Thymic Tumors, and Mesothelioma
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Past IASLC Scientific Projects
Research Grant Program
Research Grant Program
Research Grant Recipients
IASLC Academy
Publications, Resources & Guidelines
Membership
Membership
Become a Member
Renew Your Membership
Early-Career Opportunities
Partners Society Membership Offers
Patients & Caregivers
Patients & Caregivers
STARS Training
Lung Cancer Awareness Month
News
News
IASLC Lung Cancer News
WCLC 2024 News
Press Releases
Search
Fulltext search
Fulltext search
Search
Displaying 1 - 12 items out of 76 results
ILCN article
Cigarette Sales Up in U.S. for the First Time in 20 Years
ILCN article
New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer
ILCN article
Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%
ILCN article
First New Second-line Therapy for SCLC in Australia in 20 Years
ILCN article
Sotorasib Scores Second-line Approval in Canada
ILCN article
Savolitinib Approved in China for MET-Positive NSCLC
ILCN article
Durvalumab Plus Chemotherapy Approved in China as First-Line Management of Extensive-stage SCLC
ILCN article
First Comprehensive Genomic Profiling Assay Approved for Use with Brigatinib, ALK-positive NSCLC
ILCN article
Selpercatinib Approved in Canada for Metastatic NSCLC with RET Fusions
ILCN article
Sotorasib Wins Approval for Unmet Need in KRAS G12C-Driven NSCLC
ILCN article
Tepotinib Approved for MET Exon 14 Skipping Mutated Metastatic NSCLC
ILCN article
Osimertinib Approved as Adjuvant Therapy for NSCLC with Certain EGFR Mutations
Pagination
1
2
3
4
5
6
7
›
Next page
Last
Last page